Division of Diabetes and Endocrinology, Hyogo Prefectural Himeji Cardiovascular Center, Himeji, Hyogo, Japan
Research Article
Empagliflozin Ameliorating Effect of on Plasma Triglyceride: An Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
Author(s): Takahiro Sawada*, Kenzo Uzu, Naoko Hashimoto, Tetsuari Onishi, Tomohumi Takaya, Akira Shimane, Yasuyo Taniguchi, Yoshinori Yasaka, Takeshi Ohara and Hiroya Kawai
Introduction: The mechanisms behind the cardiovascular benefits of Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitors have not been fully clarified. We aimed to identify potential mechanisms underlying the favorable effects of SGLT2 inhibitors on cardiovascular events.
Methods: The 50 diabetic patients with established Coronary Artery Disease (CAD) included in this study analysis were administered 10 mg/day of empagliflozin. Cookie meal testing (carbohydrates: 75 g, fat: 28.5 g), endothelial function testing using Flow-Mediated Dilatation (FMD), and body composition evaluation were performed before and after 6 months treatments. Evaluation of changes in % FMD between treatment periods, and its association with metabolic biomarkers were evaluated.
.. View More»
DOI:
10.35248/2155-6156.19.10.827
